Streetbeat News

Analyst Ratings

HALO

Morgan Stanley analyst Vikram Purohit maintains an Overweight rating on Halozyme Therapeutics and raises the price target from $60 to $61.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 2:29 pm

JACK

RBC Capital analyst Christopher Carril has reiterated an 'Outperform' rating on Jack In The Box (NASDAQ:JACK), maintaining a price target of $110.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 2:29 pm

TMCI

Stephens & Co. analyst George Sellers maintains an Equal-Weight rating on Treace Medical Concepts (NASDAQ:TMCI) and lowers the price target from $27 to $25.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 10, 2023 | 2:28 pm

PLTR

Palantir Technologies Inc's (NYSE:PLTR) shares are trading higher, possibly due to repeated buying from Cathie Wood of Ark Invest. The company recently reported Q2 financial results in line with estimates, issued strong guidance, and announced a $1 billion buyback. Palantir also announced a multi-year partnership with Azule Energy. Several analysts adjusted price targets on the stock this week.

Portfolio Pulse from Adam Eckert

August 10, 2023 | 2:28 pm

GE

Morgan Stanley analyst Josh Sullivan maintains an Overweight rating on General Electric (NYSE:GE) and raises the price target from $122 to $125.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 2:27 pm

INFA

RBC Capital analyst Matthew Hedberg maintains an Outperform rating on Informatica (NYSE:INFA) and raises the price target from $22 to $24.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 2:26 pm

WU

Gordon Haskett has noted that Western Union's stock has been significantly undervalued, trading for less than 6x EBITDA and generating $1B of free cash flow. The firm suggests that an activist could push the company to explore its own options.

Portfolio Pulse from Happy Mohamed

August 10, 2023 | 2:26 pm

RBLX

Barclays analyst Mario Lu has maintained an Underweight rating on Roblox (NYSE:RBLX) and lowered the price target from $32 to $26.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 10, 2023 | 2:26 pm

FATE

Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Fate Therapeutics (NASDAQ:FATE) but lowered the price target from $8 to $5.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 2:25 pm

FANG

RBC Capital analyst Scott Hanold has reiterated his 'Outperform' rating on Diamondback Energy (NASDAQ:FANG), maintaining a price target of $170.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 2:24 pm